Earnings ·
Cabaletta Bio reports Q3 net loss of $53.1M and cash position of $299.4M
CABACabaletta Bio, Inc.
Cabaletta Bio reported a third-quarter 2026 net loss of $53.1 million, or $0.28 per share, compared to a $44.9 million loss in the prior-year period. Research and development expenses increased to $47.1 million from $39.8 million, while general and administrative costs rose to $7.6 million from $6.8 million. The company ended the quarter with approximately $299.4 million in cash and cash equivalents, a figure bolstered by roughly $115.0 million raised through warrant exercises. Cabaletta expects this liquidity position will fund its operating plan into the first quarter of 2028. The company is a late-stage clinical biotechnology firm developing curative targeted cell therapies for autoimmune diseases.